ACE-083 (follistatin-Fc fusion protein): preparation and storage
Intended for research use only. Not a medicinal product.
Contents (9 sections)
Structure defines the material being tested
Pearsall and colleagues describe ACE-083 as a dimeric fusion of human FST291 to human IgG2 Fc, expressed in CHO cells and distinguished from FST315-Fc. Free follistatin, a different Fc fusion or a mixture does not become ACE-083 through a similar name. [1]
Check construct boundaries, Fc isotype, supplied form and intact-protein testing for the LOT. A label saying only “follistatin peptide” needs clarification. Molarity requires the actual fusion-protein mass, not one follistatin domain or isolated Fc.
Ligand trapping versus receptor blockade
The primary study demonstrates binding and neutralization of myostatin, activins A/B and GDF11. This differs from blocking ActRII receptors with an antibody. ACE-083 and bimagrumab are therefore not interchangeable reference agents, despite being used in related signaling research. [1]
Define the ligand and endpoint required. Inhibiting one ligand does not characterize the full trap profile. Match ligand concentration, mixing order and incubation time when comparing batches; these are conditions underlying the functional result.
Extracellular matrix and binding
Pearsall separately characterizes ACE-083 affinity for heparin and extracellular matrix. Account for this when comparing media or matrix components. It does not predetermine a percentage lost to plastic; measure such recovery separately. [1]
Record medium, serum, proteins and matrix additives. Pure buffer and a matrix-containing culture are different systems. If a response changes after a medium change, investigate that variable before concluding that the protein was chemically damaged.
Preparation depends on the actual formulation
Establish whether the vial contains dry protein or solution, its buffer and carrier, and the permitted conditions. Manufacturing methods or experimental vehicles in a paper are not reconstitution instructions for any commercial LOT. Do not apply a short-peptide acid recipe to an Fc fusion without a specification.
Trial reconstitution and final-matrix compatibility on a small quantity. Record final pH, additives, concentration and time to measurement. If transfers or filtration are needed, assess recovery after the entire sequence; starting mass does not account for added handling losses.
Mass concentration, dimers and binding sites
For an educational example, 1 mg/mL to 10 µg/mL requires a 1:100 dilution. A final 1 mL mathematically uses 10 µL of stock brought to 1 mL with compatible vehicle. This is not an ACE-083 working-concentration recommendation. Match the final excipient fraction in the control.
For molarity, specify whether dimers or follistatin binding regions are counted. The primary paper describes Fc-mediated dimerization; different counting units change the reported amount. Do not assign an arbitrary “typical antibody mass” to this different protein. [1]
Functional control and intact protein
The study uses an A204 CAGA12-luciferase reporter to assess Smad2/3 signaling from different ligands, with a control reporter. This is a defined system, not a property measured by any protein assay. Specify the ligand, reference and acceptance criterion for your test. [1]
Total protein may remain similar despite a different intact-protein-to-fragment ratio. Suitable integrity and functional methods are therefore needed. Evaluate storage by comparing fresh and stored material together with matched cells and medium.
Establishing storage conditions
For dry material, “freezer for long storage, refrigerator for short use” applies only where the Fc-construct specification supports it. Planning use within a week or month does not establish a refrigerated period. A paper about the molecule does not determine another batch suitability after opening.
Solutions need buffer-, concentration- and vessel-specific data. If freezing is permitted, prepare working aliquots and maintain thaw history. Turbidity or precipitate warrants investigation, but clarity does not replace analytical suitability. Do not mix stocks with different temperature histories.
Frequently asked questions
Are ACE-083 and bimagrumab equivalent?
No. One traps ligands and the other blocks receptors; a mass conversion does not make them substitutes.
Does total protein establish intactness?
No. Check molecular state and function, not only total protein.
Can a follistatin preparation recipe be reused?
Only if validated for this Fc construct and formulation; similar names are insufficient.
Sources
- Pearsall RS et al. Follistatin-based ligand trap ACE-083 induces localized hypertrophy of skeletal muscle with functional improvement in models of neuromuscular disease. Scientific Reports, 2019. DOI (Digital Object Identifier, a permanent link to a scientific paper) verified; full text, construct, production and cell methods read. Not a shelf-life source for another commercial LOT.
Product and current sizes · Monograph and research · COA
A laboratory guide for research material; no human-use regimen is provided.
End of article
ACE-083
for laboratory research
Packs and current prices on the product page.